EASD 2026 in Milan: Dates, Hybrid Access and Research Watch Guide

EASD 2026 Annual Meeting: the direct answer

The **EASD 2026 Annual Meeting** is scheduled for **Monday 28 September to Friday 2 October 2026** at Allianz MiCo – Milan Convention Centre, Piazzale Carlo Magno 1, 20149 Milan, Italy. It is the 62nd annual meeting of the European Association for the Study of Diabetes and will run as a hybrid event, with onsite attendance in Milan and online access through the Virtual Meeting platform for registered delegates.[1] [2]

The virtual platform is already open for early access. EASD says every scientific-programme session will take place onsite at the stated Central European Summer Time, or CEST, and will be livestreamed. Recordings are to be available to registered delegates on demand until **30 October 2026**. This is registered access rather than a free public broadcast.[2]

The dates and location are also independently cross-checked by Medscape’s current meeting preview, which identifies trial results, complications, technology and obesity as major strands.[14] The programme is still subject to change: EASD reserves the right to alter speakers or arrangements and says updates will be published on its website. Use the live programme, rather than a saved social graphic, for any last-minute room or time change.[1] [3]

EASD 2026 dates and India timings

Monday 28 September is part of the meeting dates, but much of that day’s visible schedule is made up of satellite and study-group symposia. The main hall-by-hall scientific programme shown in the programme-at-a-glance runs from Tuesday 29 September to Friday 2 October. That distinction matters if you are choosing a one-day visit or building a virtual watch list.[3] [4]

All official programme times are in CEST. During the meeting, India is **three hours and 30 minutes ahead of Milan**: an 08:30 session starts at 12:00 IST, 09:30 becomes 13:00 IST, 16:30 becomes 20:00 IST and 17:30 becomes 21:00 IST. These conversions are planning aids based on the published CEST schedule; recheck the session page before joining.[2] [3]

For Indian viewers, the midday-to-evening window is workable for many highlighted sessions, while late Milan sessions extend into the night. The useful approach is to save priority sessions in MyEASD, rely on on-demand viewing where clashes occur, and note that EASD ties virtual certification to monitored watch time. Tracking blockers may prevent activity from being recorded correctly.[2] [8]

Confirmed EASD 2026 programme themes

The confirmed **EASD 2026 programme** spans basic science, clinical trials, care delivery and public health. Major strands include type 1 and type 2 diabetes, obesity, incretin therapies, cardiovascular and kidney protection, metabolic dysfunction-associated steatotic liver disease, or MASLD, glucose monitoring, automated insulin delivery, beta-cell biology, exercise, nutrition and prevention.[3] [4]

Technology is present but not treated as a single-product story. Sessions cover artificial intelligence in diabetes, imaging and multi-omics, continuous ketone monitoring, diabetes technologies during hospitalisation, and the future of sensors and algorithms. A Tuesday session specifically frames AI around responsible deployment, while another discusses AI in medical writing. Those titles confirm debate topics, not validated clinical tools or permission to replace professional judgement.[3] [4]

Implementation is another clear thread. The Wednesday EASD–ADA joint session asks how to close gaps in diabetes care, and the same morning’s session on disease-modifying drug use includes a talk by India’s Anoop Misra on the reality in Asia. Prevention, sex and gender, women’s health, early-onset type 2 diabetes and access to obesity care are also visible across the programme.[3] [4]

Guidance and consensus sessions to follow

Two sessions deserve special attention from clinicians looking for guidance rather than a single trial headline. On **Wednesday 30 September, 16:30–17:30 CEST** — **20:00–21:00 IST** — a session titled “CGM in type 2 diabetes EASD guideline” is scheduled to cover the methods, evidence synthesis, background therapy, type and frequency of continuous glucose monitoring, the overall type 2 diabetes population and the patient perspective.[3] [4]

On **Friday 2 October, 13:00–14:00 CEST** — **16:30–17:30 IST** — the programme lists an “ADA/EASD consensus report on management of type 2 diabetes”. Its published agenda focuses on the report’s methods and rationale, the context of glucose-lowering treatment, knowledge gaps and open discussion. Readers should wait for the attributable document or official society release before describing any recommendation as new policy.[3] [4]

A conference session can introduce or explain guidance, but the session title alone does not establish the final wording, evidence grade, eligible population or implementation date. Local practice in India may also depend on national guidance, regulatory approval, availability, cost, comorbidities and an individual clinician’s assessment. Do not change medicines, devices or monitoring frequency from a conference preview.[4] [12]

EASD 2026 trial-results watch guide

The first major watch point is **TRIUMPH-2** on Wednesday 30 September, 08:30–09:30 CEST, or 12:00–13:00 IST. The programme says the Phase 3 session will cover study design, baseline characteristics, efficacy, safety and conclusions for retatrutide in adults with type 2 diabetes and obesity or overweight. Lilly’s trial record identifies a planned enrolment of 1,152 and dates ending in June 2026. It does not supply the Milan presentation’s results.[4] [10]

At the same time, a SURPASS-CVOT session is scheduled to discuss longer-term glycaemic and weight outcomes, patient-reported outcomes and mortality analyses in people with type 2 diabetes and cardiovascular disease. Treat these as specified analyses within the session, not as a reason to extrapolate to lower-risk patients or to assume every outcome moves in the same direction.[4]

Thursday 1 October brings several closely watched sessions. At 08:30 CEST, or noon IST, the agenda lists the ACHIEVE programme and an efficacy-and-safety presentation comparing orforglipron with insulin glargine in ACHIEVE-4. At 09:30 CEST, or 13:00 IST, parallel sessions include **SMARTEST**, SYNCHRONIZE Phase 3 analyses of survodutide, and RESET for REMISSION in early-onset type 2 diabetes.[3] [4]

SMARTEST is especially practice-relevant because the programme asks whether an SGLT2 inhibitor should replace metformin as first-line treatment. The registry describes a Swedish, randomised, open-label trial comparing dapagliflozin with metformin in early type 2 diabetes, with 2,067 participants in the current record and macrovascular, microvascular and mortality outcomes. As of this check, ClinicalTrials.gov marks the study completed but says no results are posted. The Milan session is the source to watch; its provocative title is not a verdict.[4] [9]

Other result-bearing items include SYNCHRONIZE-2 primary data, further SYNCHRONIZE-1 analyses, and RESET for REMISSION findings on a low-energy diet plus exercise. Friday adds a session on stem-cell-derived islets in clinical trials. These involve different interventions, populations, comparators and stages of evidence, so they should not be collapsed into a single claim about a cure, superior drug or new standard of care.[4]

How to read a headline from Milan responsibly

Start with the source and release time. EASD’s media rules say an oral-presentation embargo lifts at the beginning of that presentation, while a short oral’s embargo lifts when its session begins. E-posters are embargoed until 12:00 CEST on Tuesday 29 September, unless an EASD press release gives a different time. A pre-session claim may therefore be incomplete, premature or unauthorised.[7]

Then ask four questions: Was the endpoint prespecified? What was the comparator? How large and long was the study? Were absolute benefits, adverse events, withdrawals and missing data reported? Relative changes can sound large without showing how many people were affected. Subgroup findings need particular care when the trial was not designed or powered to decide treatment for that subgroup.

Programme inclusion or an abstract is **not proof of efficacy, safety or changed clinical care**. A full assessment may require the presentation, abstract, trial registry, peer-reviewed paper, protocol, statistical analysis plan, funding and conflict disclosures, regulator decisions, and guidance from professional bodies. Patients should discuss any relevant finding with their own qualified clinician rather than stopping, starting or switching treatment on the strength of a congress headline.[4] [7] [9] [10]

Milan venue, virtual access and registration checks

For onsite delegates, the **EASD 2026 Milan venue** is Allianz MiCo. EASD directs metro users to the M5 Portello station and Gate 2 Eginardo; the venue’s own directions place Portello about 50 metres from the main entrances. Registration counters open on Sunday 27 September, and EASD recommends collecting badges that day to reduce congestion before the first main conference day.[2] [6] [11]

Security checks are mandatory under Italian rules, and EASD advises arriving early, especially for morning and highlight sessions. Large luggage can slow entry and must be left in the cloakroom rather than taken into halls. The badge is the admission pass to scientific sessions and the exhibition. Onsite attendees should check the floorplan and current gate instructions before travelling.[2]

For **EASD 2026 virtual access**, use the official Virtual Meeting platform with the MyEASD credentials linked to registration. EASD recommends a stable connection of at least 5 Mbit/s, a current browser and a desktop or laptop for full features; phones and tablets support basic viewing. Registration remains routed through the secured MyEASD system. Avoid unofficial registration, hotel and login links, which EASD specifically warns may be fraudulent.[1] [2] [5]

Why the meeting matters in India and what to check next

The meeting has direct relevance for India because the IDF Diabetes Atlas estimates that **89.8 million adults aged 20–79 in India had diabetes in 2024**, the world’s second-highest country total. The programme also addresses Asia-specific implementation, India-focused care experience and broad questions of affordability, access and long-term complication prevention. That relevance does not mean evidence from one overseas study automatically applies across India’s diverse populations and health systems.[4] [13]

Between now and 28 September, check four things: the live session timetable, your registration and platform login, any travel or room update, and the official release attached to a result you intend to cite. After a presentation, distinguish what the investigators reported from what independent experts, regulators or guideline groups later conclude. Update language from “is scheduled to present” to “reported” only after the attributable release is available.[1] [2] [4] [7]

This article is general information, not diagnosis or a treatment plan. WHO notes that diabetes can damage the heart, blood vessels, eyes, kidneys and nerves, and that management may involve lifestyle measures, medicines and screening for complications. Keep prescribed care unchanged unless your treating professional advises otherwise. If you or someone else has severe or rapidly worsening symptoms, seek urgent local medical services rather than waiting for conference news.[12]